Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections
Pharmaceutics · 03.11.2023 · 15 (11) · 2582
DOI: 10.3390/pharmaceutics15112582 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 03.11.2023. Verfasst von Yutong Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 256 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Open Project of State Key Laboratory of Respiratory Disease, Medical Scientific Research Foundation of Guangdong Province, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
Airway mucus dysfunction and impaired immunological defenses are hallmarks of several lung diseases, including asthma, cystic fibrosis, and chronic obstructive pulmonary diseases, and are mostly causative factors in bacterial-biofilm-associated respiratory tract infections. Bacteria residing within the biofilm architecture pose a complex challenge in clinical settings due to their increased tolerance to currently available antibiotics and host immune responses, resulting in chronic infections with high recalcitrance and high rates of morbidity and mortality. To address these unmet clinical needs, potential anti-biofilm therapeutic strategies are being developed to effectively control bacterial biofilm. This review focuses on recent advances in the development and application of nanoparticulate drug delivery systems for the treatment of biofilm-associated respiratory tract infections, especially addressing the respiratory barriers of concern for biofilm accessibility and the various types of nanoparticles used to combat biofilms. Understanding the obstacles facing pulmonary drug delivery to bacterial biofilms and nanoparticle-based approaches to combatting biofilm may encourage researchers to explore promising treatment modalities for bacterial-biofilm-associated chronic lung infections.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
- Department of Radiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
- The Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo 315000, China.
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou…
ORCID-Profile: Guihong Chai
Förderung
- Open Project of State Key Laboratory of Respiratory Disease
- Medical Scientific Research Foundation of Guangdong Province
- Guangdong Basic and Applied Basic Research Foundation
- Fundamental Research Funds for the Central Universities
- Open Project of The Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province
Zitieren
APA
Guo, Y., Mao, Z., Ran, F., Sun, J., Zhang, J., Chai, G., & Wang, J. (2023). Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections. Pharmaceutics, 15(11), 2582. https://doi.org/10.3390/pharmaceutics15112582
Vancouver
Guo Y, Mao Z, Ran F, Sun J, Zhang J, Chai G, et al. Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections. Pharmaceutics. 2023;15(11):2582. doi:10.3390/pharmaceutics15112582
BibTeX
@article{Guo2023,
author = {Guo, Yutong and Mao, Zeyuan and Ran, Fang and Sun, Jihong and Zhang, Jingfeng and Chai, Guihong and Wang, Jian},
title = {Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {11},
pages = {2582},
doi = {10.3390/pharmaceutics15112582}
}
EUVIMED